Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 89, Issue 11, 1992, Pages 4845-4849

  Van Zee, K J ^a   Kohno, T ^a   Fischer, E ^a   Rock, C S ^a   Moldawer, L L ^a   Lowry, S F ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

cytokine inhibitors; endotoxemia; humans; primates; septic shock

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; DRUG BINDING PROTEIN; DRUG RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR BINDING PROTEIN;

ARTICLE; BABOON; BACTEREMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; CYTOTOXICITY; DRUG INHIBITION; ENDOTOXEMIA; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; IMMUNOREACTIVITY; INFLAMMATION; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK;

ANIMAL; CELL SURVIVAL; HUMAN; INFLAMMATION; LIPOPOLYSACCHARIDES; PAPIO; RECEPTORS, CELL SURFACE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; SEPTICEMIA; SOLUBILITY; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR NECROSIS FACTOR;

PAPIO HAMADRYAS; PRIMATES;

EID: 0026741275     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.89.11.4845     Document Type: Article

References (0)